BRPI0518152A - pirazolbenzodiazepinas dissubstituìdas úteis como inibidores para cdk2 e angiogênese e para o tratamento de cánceres de mama, cólon, pulmão e próstata - Google Patents

pirazolbenzodiazepinas dissubstituìdas úteis como inibidores para cdk2 e angiogênese e para o tratamento de cánceres de mama, cólon, pulmão e próstata

Info

Publication number
BRPI0518152A
BRPI0518152A BRPI0518152-6A BRPI0518152A BRPI0518152A BR PI0518152 A BRPI0518152 A BR PI0518152A BR PI0518152 A BRPI0518152 A BR PI0518152A BR PI0518152 A BRPI0518152 A BR PI0518152A
Authority
BR
Brazil
Prior art keywords
colon
cdk2
breast
angiogenesis
lung
Prior art date
Application number
BRPI0518152-6A
Other languages
English (en)
Inventor
Jin-Jun Liu
Kin-Chun Luk
Giacomo Pizzolato
Yi Ren
Kshitij Chhabilbhai Thakkar
Peter Michael Wovkulich
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0518152(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0518152A publication Critical patent/BRPI0518152A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

PIRAZOLBENZODIAZEPINAS DISSUBSTITUìDAS úTEIS COMO INIBIDORES PARA CDK2 E ANGIOGéNESE E PARA O TRATAMENTO DE CáNCERES DE MAMA, CóLON, PULMãO E PRóS-TATA. A presente invenção provê compostos da fórmula (I) onde R˜, R, R e R¬ 4¬ são descritos aqui. A invenção também provê síntese para preparação de tais compostos e composições farmacêuticas contendoos. A invenção provê ainda métodos para inibição de cinases, em particular CDK2, para inibição de angiogênese e para tratamento de cânceres, em particular cânceres de mama, cólon, próstata e pulmão.
BRPI0518152-6A 2004-10-13 2005-10-04 pirazolbenzodiazepinas dissubstituìdas úteis como inibidores para cdk2 e angiogênese e para o tratamento de cánceres de mama, cólon, pulmão e próstata BRPI0518152A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61817404P 2004-10-13 2004-10-13
PCT/EP2005/010653 WO2006040036A1 (en) 2004-10-13 2005-10-04 Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer

Publications (1)

Publication Number Publication Date
BRPI0518152A true BRPI0518152A (pt) 2008-11-04

Family

ID=35311946

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518152-6A BRPI0518152A (pt) 2004-10-13 2005-10-04 pirazolbenzodiazepinas dissubstituìdas úteis como inibidores para cdk2 e angiogênese e para o tratamento de cánceres de mama, cólon, pulmão e próstata

Country Status (25)

Country Link
US (1) US7524840B2 (pt)
EP (1) EP1802625B1 (pt)
JP (1) JP2008515939A (pt)
KR (1) KR100858262B1 (pt)
CN (2) CN101039946B (pt)
AR (1) AR051326A1 (pt)
AT (1) ATE398619T1 (pt)
AU (1) AU2005293818A1 (pt)
BR (1) BRPI0518152A (pt)
CA (1) CA2582985A1 (pt)
DE (1) DE602005007623D1 (pt)
DK (1) DK1802625T3 (pt)
ES (1) ES2308551T3 (pt)
HR (1) HRP20080429T3 (pt)
IL (1) IL182423A0 (pt)
MX (1) MX2007004464A (pt)
NO (1) NO20071794L (pt)
NZ (1) NZ554353A (pt)
PL (1) PL1802625T3 (pt)
PT (1) PT1802625E (pt)
RU (1) RU2394826C2 (pt)
SI (1) SI1802625T1 (pt)
TW (1) TWI309652B (pt)
WO (1) WO2006040036A1 (pt)
ZA (1) ZA200702973B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
AU2006301292A1 (en) * 2005-10-14 2007-04-19 F. Hoffmann-La Roche Ag Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo (3, 4.-b) (1, 4) benzodiazepine
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
SI2432472T1 (sl) * 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
JP2011201794A (ja) * 2010-03-24 2011-10-13 Fujifilm Corp ５−アミノピラゾール誘導体及びその塩の製造方法
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN103626761B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
CN106928040A (zh) * 2015-12-31 2017-07-07 上海医药工业研究院 Sglt2抑制剂中间体的制备方法
CA3046809A1 (en) * 2016-12-12 2018-06-21 The University Of Sydney Non-peptide oxytocin receptor agonists
RS66947B1 (sr) * 2016-12-13 2025-07-31 Transthera Sciences Nanjing Inc Jedinjenje inhibitora više kinaza, i njegova kristalna forma i upotreba
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
EP4574823A1 (en) 2022-08-17 2025-06-25 Korea Research Institute of Chemical Technology Compounds for inhibiting or decomposing cdk2 and/or cdk9, and medicinal uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681341A (en) 1970-12-23 1972-08-01 Hoffmann La Roche Process for preparing 1-lower alkyl-1,4-benzodiazepin-2-ones
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
ZA889116B (en) * 1987-12-18 1989-08-30 Hoffmann La Roche Tricyclic compounds
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
PL362835A1 (en) * 2000-12-01 2004-11-02 Ajinomoto Co,Inc. Lactam compounds and medicinal use thereof

Also Published As

Publication number Publication date
RU2007117770A (ru) 2008-11-20
HRP20080429T3 (en) 2008-09-30
WO2006040036A1 (en) 2006-04-20
KR100858262B1 (ko) 2008-09-11
JP2008515939A (ja) 2008-05-15
CN101899049A (zh) 2010-12-01
PL1802625T3 (pl) 2008-12-31
NZ554353A (en) 2010-01-29
US20060079511A1 (en) 2006-04-13
US7524840B2 (en) 2009-04-28
PT1802625E (pt) 2008-08-06
EP1802625B1 (en) 2008-06-18
ATE398619T1 (de) 2008-07-15
RU2394826C2 (ru) 2010-07-20
AR051326A1 (es) 2007-01-03
EP1802625A1 (en) 2007-07-04
SI1802625T1 (sl) 2008-10-31
AU2005293818A1 (en) 2006-04-20
CN101039946A (zh) 2007-09-19
KR20070054243A (ko) 2007-05-28
CN101039946B (zh) 2010-12-08
CA2582985A1 (en) 2006-04-20
ES2308551T3 (es) 2008-12-01
IL182423A0 (en) 2007-07-24
TW200628469A (en) 2006-08-16
TWI309652B (en) 2009-05-11
DE602005007623D1 (de) 2008-07-31
ZA200702973B (en) 2009-09-30
DK1802625T3 (da) 2008-09-01
HK1108284A1 (en) 2008-05-02
NO20071794L (no) 2007-07-10
MX2007004464A (es) 2007-05-07

Similar Documents

Publication Publication Date Title
BRPI0518152A (pt) pirazolbenzodiazepinas dissubstituìdas úteis como inibidores para cdk2 e angiogênese e para o tratamento de cánceres de mama, cólon, pulmão e próstata
BRPI0511975A (pt) pirazolopirimidinas
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
NO20081952L (no) Substituerte pyrazolforbindelser
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
EA201201154A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
MX2012003311A (es) Inhibidores de miristato de moleculas pequeñas contra bcr-abl y metodos de uso.
DE602006012672D1 (de) Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen
TW200800963A (en) Chemical compounds
PL1853602T3 (pl) Związki chemiczne
PT1853588E (pt) Compostos químicos
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
TNSN08020A1 (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
MXPA05006507A (es) Inhibidores de ccxckr2 expresado en tumor humano.
WO2013066485A3 (en) Compositions and methods for treatment of metastatic cancer
ATE435224T1 (de) Neue piperidinsubstituierte diaminothiazole
GB2469980A (en) Novel napthalimide-benzimidazole hybrids as potential antitumour agents and process for the preparation thereof
BRPI0816823A8 (pt) Formulação contendo composto inibidor de quinase dependente de ciclina e método de tratamento de tumores que a utiliza
DE502004007950D1 (en) Antitumor wirksame 2-substituierte d-homoestra-1,3,5(10)-trien-3-yl sulfamate
TW200621270A (en) Novel use of nanogold for manufacturing medicaments for inhibiting metastasis of malignant tumors and growth of leukemic cells, and pharmaceutical compositions for inhibiting metastasis of malignant tumors and for treating leukemia comprising nanogold

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2208 DE 30/04/2013.